WGS Stock Price Today (November 2026) — GeneDx Holdings Corp. Analysis & Key Metrics 2026-11-06
GeneDx Holdings Corp. (WGS) is trading at $62.37, down 3.09% today (as of November 2026).The stock is trading below its 50-day and 200-day moving averages.
- According to consensus analyst estimates, the 1-year price target is $93.50 (49.9% upside).
- Volatility is high (104.78% annualized), above 40%.
- From the latest financial filings: Revenue grew 11.40% in the latest quarter compared with the same quarter a year earlier. Debt is 0.69 times shareholders' equity.
WGS Stock Analysis: Key Metrics & Valuation (November 2026)
Key figures from the latest data
GeneDx Holdings Corp. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $1.89B
P/E Ratio
Forward P/E: 52.04
Revenue Growth
Latest quarter vs year ago
Analyst Target
+49.9% upside potential
Key Investor Questions About WGS
What the latest data shows
WGS is trading below its 50-day and 200-day moving averages, and its RSI of 42.5 is in the neutral zone (between 30 and 70).
- Technicals: Neutral (RSI 42.51) (Downtrend: below 50- and 200-day averages)
- Fundamentals: Revenue +11.4%, debt/equity 0.69x
Revenue grew 11.40% in the latest quarter compared with the same quarter a year earlier.
- Total debt is $167.40M (0.69 times equity).
- 30-day volatility is 104.78% annualized, which counts as high (above 40%).
52-Week Trading Range
Over the past year, WGS stock traded between $32.21 and $170.87 and currently trades in the middle of that range.
Volatility & Risk Profile
30-day volatility is 104.78% annualized, which counts as high (above 40%). Beta 1.72: the stock has moved much more than the market.
Institutional & Insider Ownership
Short interest is 38.65% of the float.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines, coverage and TickZen analysis
Market news
Earnings to Watch: GeneDx Holdings Corp (WGS) Q3 2026 -- GF Value Sees 44.00% Upside
GeneDx Holdings And 2 Other Top Healthcare Stocks
GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026
How Long Can GeneDx Keep Burning Cash?
GeneDx to Add Long-Read Whole Genome Sequencing to Testing Portfolio
Latest TickZen Insights
All insights →No TickZen article on WGS yet. Our newest analysis:
Explore More Analysis for WGS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 9, 2026 (after the close)
Frequently Asked Questions
Common investor questions about GeneDx Holdings Corp.
GeneDx Holdings Corp. (WGS) is currently trading at $62.37. The RSI (14-day) is 42.5, in the neutral zone (between 30 and 70). Wall Street analysts have a consensus "Strong Buy" recommendation. The mean analyst price target of $93.50 implies 49.9% upside from current levels. 30-day volatility is 104.78% annualized, which counts as high (above 40%).
Based on current valuation metrics for GeneDx Holdings Corp. (WGS): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 52.04. Price-to-Book is 7.61. Price-to-Sales is 4.09. Different industries trade at different multiples, so these figures are most useful next to Diagnostics & Research peers.
Based on 8 analysts covering WGS, the consensus price target is $93.50. This represents a 49.9% upside from the current price of $62.37. The range spans from a low target of $83.00 to a high target of $103.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "Strong Buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
GeneDx Holdings Corp. (WGS) does not currently pay a regular dividend.
Key risks for GeneDx Holdings Corp. (WGS) shown in the latest data: 1. High volatility (104.8% annualized, above 40%). 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Elevated short interest (38.6% of float). 4. Moves in the broader stock market (Beta 1.72: the stock has moved much more than the market).
Here is GeneDx Holdings Corp.'s (WGS) current debt and financial health profile: Total debt stands at $167.40M. The debt-to-equity ratio is 0.69x, which is moderate and generally manageable for most companies. The current ratio is 3.30, indicating strong short-term liquidity. The quick ratio is 2.90. The company holds $132.55M in cash and equivalents. Free cash flow is negative at -$75.80M, which could limit the company's ability to manage debt obligations.